Story
AstraZeneca Inks $1.5 Billion Deal for Global Rights to Dizal's Lung Cancer Treatment
Summary
AstraZeneca will pay Dizal Pharmaceutical an upfront sum of $600 million for the global rights to its lung cancer drug, Sunvozertinib, with the total deal value potentially reaching $1.5 billion.
AstraZeneca (LON:AZN) has agreed to acquire the exclusive global development and commercialization rights for the lung cancer drug Sunvozertinib from China-based Dizal Pharmaceutical (SHA:688192). The deal includes a $600 million upfront payment and could be worth up to $1.5 billion in total.
Financial Terms of the Agreement
According to a filing with the Shanghai stock exchange by Dizal, the agreement's structure includes the initial $600 million cash payment to the Chinese drugmaker. In addition to the upfront sum, Dizal is eligible to receive up to $900 million in further payments contingent on achieving specific clinical development and sales-related milestones.
This transaction grants AstraZeneca the worldwide rights to develop and market Sunvozertinib, significantly expanding its oncology portfolio.
A Closer Look at Sunvozertinib
Sunvozertinib, also marketed as Zegfrovy, is an oral treatment already approved in the United States and China for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC). This type of cancer is highly prevalent, accounting for approximately 77% of all lung cancer cases, according to the American Cancer Society.
AdA late-stage multinational clinical trial involving 324 patients demonstrated the drug's efficacy. Patients treated with Sunvozertinib achieved a median progression-free survival of 10.3 months, compared to 7.5 months for those receiving standard chemotherapy.
Strategic Importance for AstraZeneca
The acquisition reinforces AstraZeneca's strategic focus on its oncology business, a key driver of the company's growth. The deal brings a proven, targeted therapy into its pipeline for a patient population with a significant unmet need.
"With this agreement, we will bring a differentiated, oral targeted treatment to these patients with limited options across the globe," said Dave Fredrickson, Executive Vice President of AstraZeneca's Oncology Haematology Business Unit, in a statement.